A Single-center, Non-randomized, Open-label Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal Cancer
Latest Information Update: 16 Feb 2026
At a glance
- Drugs Neoantigens reactive T cell therapy (Primary) ; XH 001 (Primary)
- Indications Gastrointestinal cancer
- Focus Adverse reactions
Most Recent Events
- 12 Feb 2026 Planned End Date changed from 1 Oct 2029 to 1 Aug 2027.
- 12 Feb 2026 Planned primary completion date changed from 1 Jul 2027 to 1 Feb 2026.
- 12 Feb 2026 Status changed from not yet recruiting to recruiting.